Arginase Treatment Prevents the Recovery of Canine Lymphoma and Osteosarcoma Cells Resistant to the Toxic Effects of Prolonged Arginine Deprivation

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wells, James W ^a   Evans, Christopher H ^a   Scott, Milcah C ^b   Rütgen, Barbara C ^c   O'Brien, Timothy D ^d   Modiano, Jaime F ^b   Cvetkovic, Goran ^e   Tepic, Slobodan ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Kyon AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; ASPARAGINASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; HEMATOPOIETIC STEM CELL; LYMPHOID CELL LINE; LYMPHOMA; NONHUMAN; OSTEOSARCOMA; TREATMENT DURATION;

ADULT STEM CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGINASE; ARGININE; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA; DOGS; LEUKEMIA; LYMPHOMA; OSTEOSARCOMA;

CANIS FAMILIARIS;

EID: 84872857859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054464     Document Type: Article

References (35)

1. Wheatley DN, (2005) Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Seminars in cancer biology 15: 247-53.
2. Lamb J, Wheatley DN, (2000) Single amino acid (arginine) deprivation induces G1 arrest associated with inhibition of cdk4 expression in cultured human diploid fibroblasts. Experimental cell research 255: 238-49.
3. Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, et al. (2011) Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment cell & melanoma research 24: 366-76.
4. Scott L, Lamb J, Smith S, Wheatley DN, (2000) Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. British journal of cancer 83: 800-10.
5. Yau T, Cheng PN, Chan P, Chan W, Chen L, et al. (2012) A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Investigational new drugs.
6. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, et al. (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. Journal of clinical oncology 22: 1815-22.
7. Morris JG, Rogers QR, (1978) Arginine: an essential amino acid for the cat. The Journal of nutrition 108: 1944-53.
8. Morris JG, (1985) Nutritional and metabolic responses to arginine deficiency in carnivores. The Journal of nutrition 115: 524-31.
9. Modiano JF, Breen M, Avery AC, London CA, (2006) Breed-specific Canine Lymphoproliferative Diseases. Cold Spring Harb Mon 44: 439-50.
10. Priester WA, McKay FW, (1980) The occurrence of tumors in domestic animals. National Cancer Institute monograph pp. 1-210.
11. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR, (1968) Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 40: 307-18.
12. Onions DE, (1984) A prospective survey of familial canine lymphosarcoma. Journal of the National Cancer Institute 72: 909-12.
13. Teske E, de Vos JP, Egberink HF, Vos JH, (1994) Clustering in canine malignant lymphoma. The Veterinary quarterly 16: 134-6.
14. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM, (2002) Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of veterinary internal medicine 16: 704-9.
15. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, et al. (2005) Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer research 65: 5654-61.
16. Modiano JF, Breen M, Lana SE, Ehrhart N, Fosmire SP, et al. (2006) Naturally occurring translational models for development of cancer gene therapy. Gene Ther Mol Biol 10A: 31-40.
17. Phillips JC, Stephenson B, Hauck M, Dillberger J, (2007) Heritability and segregation analysis of osteosarcoma in the Scottish deerhound. Genomics 90: 354-63.
18. Ru G, Terracini B, Glickman LT, (1998) Host related risk factors for canine osteosarcoma. Veterinary journal 156: 31-9.
19. Withrow SJ, Powers BE, Straw RC, Wilkins RM, (1991) Comparative aspects of osteosarcoma. Dog versus man. Clinical orthopaedics and related research pp. 159-68.
20. Nakaichi M, Taura Y, Kanki M, Mamba K, Momoi Y, et al. (1996) Establishment and characterization of a new canine B-cell leukemia cell line. The Journal of veterinary medical science 58: 469-71.
21. Rutgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al. (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leukemia research 34: 932-8.
22. Steplewski Z, Jeglum KA, Rosales C, Weintraub N, (1987) Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer immunology, immunotherapy 24: 197-201.
23. Momoi Y, Okai Y, Watari T, Goitsuka R, Tsujimoto H, et al. (1997) Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Veterinary immunology and immunopathology 59: 11-20.
24. Kisseberth WC, Nadella MV, Breen M, Thomas R, Duke SE, et al. (2007) A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leukemia research 31: 1709-20.
25. Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, et al. (2011) Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 49: 356-67.
26. Wheatley DN, Campbell E, (2002) Arginine catabolism, liver extracts and cancer. Pathology oncology research 8: 18-25.
27. Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PN, et al. (2012) Deprivation of arginine by recombinant human arginase in prostate cancer cells. Journal of hematology & oncology 5: 17.
28. Bobak YP, Vynnytska BO, Kurlishchuk YV, Sibirny AA, Stasyk OV, (2010) Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell biology international 34: 1085-9.
29. Wheatley DN, Campbell E, (2003) Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells. British journal of cancer 89: 573-6.
30. Philip R, Campbell E, Wheatley DN, (2003) Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. British journal of cancer 88: 613-23.
31. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, et al. (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117: 238-49.
32. Jorck C, Kiess W, Weigel JF, Mutze U, Bierbach U, et al. (2011) Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatric hematology and oncology 28: 3-9.
33. Muller HJ, Boos J, (1998) Use of L-asparaginase in childhood ALL. Critical reviews in oncology/hematology 28: 97-113.
34. Raetz EA, Salzer WL, (2010) Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. Journal of pediatric hematology/oncology 32: 554-63.
35. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, et al. (2010) Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 115: 5214-21.